DOR BIOPHARMA INC Form SC 13G/A February 14, 2008

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

#### SCHEDULE 13G/A1

Under the Securities Exchange Act of 1934

(Amendment No. 1)

DOR BioPharma, Inc.

(Name of Issuer)

Common Stock, Par Value \$0.001 per share

(Title of Class of Securities)

258094101

(CUSIP Number)

December 31, 2007

(Date of Event which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

- o Rule 13d-1(b)
- x Rule 13d-1(c)
- o Rule 13d-1(d)

<sup>\*</sup>The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

1. Names of Reporting Persons. I.R.S. Identification Nos. of above persons (entities only). Paolo Cavazza 2. Check the Appropriate Box if a Member of a Group (See Instructions) (a) o (b) o 3. SEC Use Only 4. Citizenship or Place of Organization Italy 5. Sole Voting Power 1,546,870 Number of 6. **Shared Voting Power** Shares Beneficially Owned by Each Sole Dispositive Power 7. Reporting Person With: 1,546,870 8. Shared Dispositive Power 0 Aggregate Amount Beneficially Owned by Each Reporting Person 1,546,870 10. Check box if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) 11. Percent of Class Represented by Amount in Row (9) 1.6% (based on 94,774,187 shares of common stock outstanding as of November 7, 2007, as reported in the Issuer's prospectus supplement filed with the Securities and Exchange Commission on November, 19, 2007) 12. Type of Reporting Person (See Instructions) IN

1. Names of Reporting Persons. I.R.S. Identification Nos. of above persons (entities only). Claudio Cavazza 2. Check the Appropriate Box if a Member of a Group (See Instructions) (a) o (b) o 3. SEC Use Only Citizenship or Place of Organization Italy 5. Sole Voting Power Number of **Shared Voting Power** 6. Shares Beneficially Owned by Each Sole Dispositive Power 7. Reporting Person With: 0 8. **Shared Dispositive Power** 0 9. Aggregate Amount Beneficially Owned by Each Reporting Person 0 10. Check box if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) 11. Percent of Class Represented by Amount in Row (9) 0% (based on 94,774,187 shares of common stock outstanding as of November 7, 2007, as reported in the Issuer's prospectus supplement filed with the Securities and Exchange Commission November 19, 2007) 12. Type of Reporting Person (See Instructions) IN

-3-

1. Names of Reporting Persons. I.R.S. Identification Nos. of above persons (entities only). Sigma-Tau Finanziaria S.p.A. 2. Check the Appropriate Box if a Member of a Group (See Instructions) (a) o (b) o 3. SEC Use Only 4. Citizenship or Place of Organization Italy 5. Sole Voting Power **Shared Voting Power** Number of 6. Shares Beneficially Owned by Each Sole Dispositive Power 7. Reporting Person With: 0 8. **Shared Dispositive Power** 0 9. Aggregate Amount Beneficially Owned by Each Reporting Person 0 10. Check box if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) 11. Percent of Class Represented by Amount in Row (9) 0% (based on 94,774,187 shares of common stock outstanding as of November 7, 2007, as reported in the Issuer's prospectus supplement filed with the Securities and Exchange Commission November 19, 2007) 12. Type of Reporting Person (See Instructions) CO

-4-

1. Names of Reporting Persons. I.R.S. Identification Nos. of above persons (entities only). Sigma-Tau International S.A. 2. Check the Appropriate Box if a Member of a Group (See Instructions) (a) o (b) o 3. SEC Use Only 4. Citizenship or Place of Organization Luxembourg 5. Sole Voting Power Number of Shared Voting Power 6. Shares Beneficially Owned by Each Sole Dispositive Power 7. Reporting Person With: Shared Dispositive Power 8. 0 9. Aggregate Amount Beneficially Owned by Each Reporting Person 0 10. Check box if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) o 11. Percent of Class Represented by Amount in Row (9) 0% (based on 94,774,187 shares of common stock outstanding as of November 7, 2007, as reported in the Issuer's prospectus supplement filed with the Securities and Exchange Commission November 19, 2007) 12. Type of Reporting Person (See Instructions) CO

-5-

1. Names of Reporting Persons. I.R.S. Identification Nos. of above persons (entities only). Sigma-Tau America S.A. 2. Check the Appropriate Box if a Member of a Group (See Instructions) (a) o (b) o 3. SEC Use Only 4. Citizenship or Place of Organization Luxembourg 5. Sole Voting Power Number of **Shared Voting Power** 6. Shares Beneficially Owned by Each Sole Dispositive Power 7. Reporting Person With: 8. **Shared Dispositive Power** 0 9. Aggregate Amount Beneficially Owned by Each Reporting Person 0 10. Check box if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) o 11. Percent of Class Represented by Amount in Row (9) 0% (based on 94,774,187 shares of common stock outstanding as of November 7, 2007, as reported in the Issuer's prospectus supplement filed with the Securities and Exchange Commission November 19, 2007) 12. Type of Reporting Person (See Instructions) CO

-6-

1. Names of Reporting Persons.

I.R.S. Identification Nos. of above persons (entities only).

Sigma-Tau Pharmaceuticals, Inc. On October 25, 2007, Sigma-Tau Pharmaceuticals, Inc. was merged into Sigma-Tau Holding America, Inc., which survived and changed its name to Sigma-Tau Pharmaceuticals, Inc.

2. Check the Appropriate Box if a Member of a Group

(See

Instructions)

(a) o

(b) o

- 3. SEC Use Only
- 4. Citizenship or Place of Organization

Nevada

5. Sole Voting Power

0

Number of Shares Beneficially

Owned by Each Reporting

Person With:

Shared Voting Power 6.

0

7. Sole Dispositive Power

0

8. Shared Dispositive Power

0

9. Aggregate Amount Beneficially Owned by Each Reporting Person

10. Check box if the Aggregate Amount in Row (9) Excludes

Certain Shares (See

Instructions)

11. Percent of Class Represented by Amount in Row (9)

0% (based on 94,774,187 shares of common stock outstanding as of November 7, 2007, as reported in the Issuer's prospectus supplement filed with the Securities and Exchange Commission November 19, 2007)

12. Type of Reporting Person (See Instructions)

CO

Item 1(a). Name of Issuer: DOR BioPharma, Inc. Item 1(b). Address of Issuer's Principal Executive Offices: 1101 Brickell Avenue, Suite 701-S, Miami FL 33131 Name of Person Filing: Item 2(a). This statement is filed on behalf of each of the following persons (collectively, the "Reporting Persons") Paolo Cavazza (i) (ii) Claudio Cavazza Sigma-Tau Finanziaria S.p.A. ("Sigma-Tau") (iii) Sigma-Tau International S.A. (iv) Sigma-Tau America S.A. (v) Sigma-Tau Pharmaceuticals, Inc. (vi) Item 2(b). Address of Principal Business Office: (i) Paolo Cavazza Via Tesserete 10 Lugano, Switzerland (ii) Claudio Cavazza Via Sudafrica, 20 Rome, Italy 00144 (iii) Sigma-Tau Via Sudafrica, 20 Rome, Italy 00144 (iv) Sigma-Tau International S.A. 19-21 Boulevard du Prince Henri L-1724 Luxembourg

(v)

Sigma-Tau America S.A.

L-1724 Luxembourg

19-21 Boulevard du Prince Henri

(vi) Sigma-Tau Pharmaceuticals, Inc. 800 South Frederick Avenue, Suite 300 Gaithersburg, Maryland 20877 **USA** Item 2(c). Citizenship: (i) Paolo Cavazza is an Italian citizen. Claudio Cavazza is an Italian citizen. (ii) (iii) Sigma-Tau is an Italian corporation. Sigma-Tau International S.A. is a Luxembourg corporation. (iv) (v) Sigma-Tau America S.A. is a Luxembourg corporation. Sigma-Tau Pharmaceuticals, Inc. is a Nevada corporation. (vi) Title of Class of Securities: Item 2(d). Common Stock, par value \$0.001 (the "Shares") **CUSIP** Number: Item 2(e). 258094101 Item 3. If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person is a: This Item 3 is not applicable -9-

Item 4.	Ownership:		
Paolo Cava	zza		
(a)	Amount beneficially owned: 1,546,870		
(b)	Percent of class: 1.6%		
(c)	Number of shares as to which such person has:  (i) sole power to vote or to direct the vote:  (ii) shared power to vote or to direct the vote:  (iii) sole power to dispose or to direct the disposition of:  (iv) shared power to dispose or to direct the disposition of:  0  1,546,870  1,546,870  0		
Claudio Cav	vazza		
(a)	Amount beneficially owned:		0
(b)	Percent of class:		0%
(c)	Number of shares as to which such person has: (i) sole power to vote or to direct the vote: (ii) shared power to vote or to direct the vote: (iii) sole power to dispose or to direct the disposition of: (iv) shared power to dispose or to direct the disposition of:		0 0 0 0
Sigma Tau			
(a)	Amount beneficially owned:		0
(b)	Percent of class:		0%
(c)	Number of shares as to which such person has: <ol> <li>sole power to vote or to direct the vote:</li> <li>shared power to vote or to direct the vote:</li> <li>sole power to dispose or to direct the disposition of:</li> <li>shared power to dispose or to direct the disposition of:</li> </ol>		0 0 0 0
-10-			

(a)	Amount beneficially owned:	0
(b)	Percent of class:	0%
(c)	Number of shares as to which such person has:	
	(i) sole power to vote or to direct the vote:	0
	(ii) shared power to vote or to direct the vote:	0
	(iii) sole power to dispose or to direct the disposition of:	0
	(iv) shared power to dispose or to direct the disposition of:	0
Sigma-Tau <i>A</i>	America S.A.	
(a)	Amount beneficially owned:	0
(b)	Percent of class:	0%
(c)	Number of shares as to which such person has:	
	(i) sole power to vote or to direct the vote:	0
	(ii) shared power to vote or to direct the vote:	0
	(iii) sole power to dispose or to direct the disposition of:	0
	(iv) shared power to dispose or to direct the disposition of:	0
Sigma-Tau F	Pharmaceuticals, Inc.	
(a)	Amount beneficially owned:	0
(b)	Percent of class:	0%
(c)	Number of shares as to which such person has:	
	(i) sole power to vote or to direct the vote:	0
	(ii) shared power to vote or to direct the vote:	0
	(iii) sole power to dispose or to direct the disposition of:	0
	(iv) shared power to dispose or to direct the disposition of:	0
-11-		

Item 5.	Ownership of Five Percent or Less of a Class:		
Yes			
Item 6.	Ownership of More than Five Percent on Behalf of Another Person:		
Not Applicable			
tem Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company:			
Not Applicable			
Item 8.	Identification and Classification of Members of the Group:		
Not Applicable			
Item 9.	Notice of Dissolution of Group:		
Not Applicable			
Item 10.	Certification:		
By signing below, I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.			
-12-			

#### **SIGNATURE**

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Dated: February 13, 2008 PAOLO CAVAZZA

By: /s/ Antonio Nicolai Name: Antonio Nicolai

Title: proxy holder authorized

Dated: February 13, 2008 CLAUDIO CAVAZZA

By: /s/ Antonio Nicolai Name: Antonio Nicolai

Title: proxy holder authorized

Dated: February 13, 2008

SIGMA-TAU FINANZIARIA SPA

By: /s/ Antonio Nicolai Name: Antonio Nicolai

Title: Director - proxy holder authorized

Dated: February 13, 2008

SIGMA-TAU INTERNATIONAL S.A.

By: /s/ Gregg Lapointe
Name: Gregg Lapointe
Title: Attorney-in-fact

Dated: February 13, 2008 SIGMA-TAU AMERICA S.A.

By: /s/ Gregg Lapointe
Name: Gregg Lapointe
Title: Attorney-in-fact

Dated: February 13, 2008

SIGMA-TAU PHARMACEUTICALS, INC.

By: /s/ Gregg Lapointe Name: Gregg Lapointe

Title: Chief Operating Officer

-14-

#### **EXHIBIT INDEX**

- A. Joint Filing Agreement dated January 12, 2007 by and among Paolo Cavazza, Claudio Cavazza, Sigma Tau Finanziaria S.p.A., Sigma-Tau Pharmaceuticals, Inc., Sigma Tau America S.A., Sigma-Tau Holding America, Inc. and Sigma Tau International S.A.1
- B. Power of Attorney, dated January 9, 2007, granted by Messrs. Dominique Audia and Luca Checchinato, directors of Sigma-Tau International S.A., in favor of Messrs. Gregg Lapointe and Don DeLillo<u>2</u>
- C. Power of Attorney, dated January 9, 2007, granted by Messrs. Dominique Audia and Luca Checchinato, directors of Sigma-Tau America S.A., in favor of Messrs. Gregg Lapointe and Don DeLillo3
- D. Power of Attorney, dated January 10, 2007, granted by Mr. Paolo Cavazza in favor of Messrs. Antonio Nicolai and Maurizio Terenzi4
- E. Power of Attorney, dated January 10, 2007, granted by Mr. Claudio Cavazza, President of Sigma-Tau Finanziaria S.p.A., in favour of Messrs. Antonio Nicolai and Maurizio Terenzi<u>5</u>
- F. Power of Attorney, dated January 10, 2007, granted by Mr. Claudio Cavazza in favor of Messrs. Antonio Nicolai and Maurizio Terenzi<u>6</u>
- 1 Incorporated by reference to the Reporting Person's Schedule 13G filed with the SEC on January 12, 2007
- 2 Incorporated by reference to the Reporting Person's Schedule 13G filed with the SEC on January 12, 2007.
- 3 Incorporated by reference to the Reporting Person's Schedule 13G filed with the SEC on January 12, 2007.
- 4 Incorporated by reference to the Reporting Person's Schedule 13G filed with the SEC on January 12, 2007.
- 5 Incorporated by reference to the Reporting Person's Schedule 13G filed with the SEC on January 12, 2007.
- 6 Incorporated by reference to the Reporting Person's Schedule 13G filed with the SEC on January 12, 2007.